Prevalence of MAFLD in Patients With Type 2 Diabetes in Jiangsu Province of China

Launched by WUXI HISKY MEDICAL TECHNOLOGY CO LTD · Oct 24, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at how common a condition called Metabolic Associated Fatty Liver Disease (MAFLD) is among patients with Type 2 Diabetes in Jiangsu Province, China. Type 2 Diabetes is a serious health issue that affects many people worldwide and can lead to other problems, including fatty liver disease. The study aims to better understand how these two conditions are linked, especially since many people with diabetes also have fatty liver disease, which is often connected to issues like obesity and high blood pressure.

To participate in this study, you need to be diagnosed with Type 2 Diabetes according to specific guidelines and be willing to attend regular follow-ups. Unfortunately, if you have another type of diabetes or cannot keep up with the study's requirements, you won't be eligible. If you join, you'll help researchers gather important information that could lead to better care for people with Type 2 Diabetes and related health issues. This is a great opportunity to contribute to research that may improve understanding and treatment options for these conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosed as T2DM according to the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes
• • UAP were measured based on iLivTouch
• • Willing to attend this study and able to provide the written informed consent.
• Exclusion Criteria:
• • Other types of diabetes
• • Patients unable to receive regular follow-up